AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Korábbi kezelés

• Patients eligible to hematopoietic stem cell transplantation (HSCT) at the time of inclusion
• Patients with HSCT within 100 days prior to the first administration of AB8939
• Patients eligible to hematopoietic stem cell transplantation (HSCT) at the time of inclusion
• Patients with HSCT within 100 days prior to the first administration of AB8939

Egyéb

• Patients eligible to a standard of care
• Patients diagnosed with acute promyelocytic leukemia (M3)
• Patients with clinically active CNS leukemia
• Women who are lactating/breastfeeding or who plan to breastfeed while on study
• Women with a positive pregnancy test
  • Other protocol-defined inclusion/exclusion criteria may apply
  • EXPANSION COHORT STUDY
• Patients eligible to a standard of care
• Patients diagnosed with acute promyelocytic leukemia (M3)
• Patients with clinically active CNS leukemia
• Women who are lactating/breastfeeding or who plan to breastfeed while on study
• Women with a positive pregnancy test
  • Other protocol-defined inclusion/exclusion criteria may apply

• Patients with documented diagnosis of acute myeloid leukemia (AML) based on the last version of the World Health Organization classification and eligible to second or third line of treatment.
• Patients with documented diagnosis of refractory melyodisplastic syndrome in second or third line of treatment, and with high risk at prognosis based on the IPSS-R scoring system.
• ECOG performance status ≤ 1
• Patients are able to understand, sign, and date the written informed consent form at screening visit prior to any protocol-specific procedures
• Patients are able and willing to comply with study procedures as per protocol, including bone marrow biopsies
• Patients with documented diagnosis of acute myeloid leukemia (AML) based on the last version of the World Health Organization classification and eligible to second or third line of treatment.
• ECOG performance status ≤ 2
• Patients are able to understand, sign, and date the written informed consent form at screening visit prior to any protocol-specific procedures
• Patients are able and willing to comply with study procedures as per protocol, including bone marrow biopsies

A regiszterben nem jelölt feltételek

• DOSE ESCALATION STUDY